NR in Chemo-induced Peripheral Neuropathy

Major Program
Supportive Care and Symptom Management
Research Group
Community Oncology and Prevention Trials
Donna Hammond, PhD
Terminated ID
For more information, see NCT03642990
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.
Nicotinamide Riboside
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV, Endometrial Cancer Stage IV
Donna L Hammond, PhD, Alexandra Thomas, MD

See list of participating sites